Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...
MedPage Today on MSN
Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1
Del-desiran reduced DMPK mRNA levels, but led to two serious adverse events ...
Patrick Cornell, known as Vroom Old Man, is riding 200,000 miles in a single year to raise $125,000 for myotonic dystrophy.
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, ...
Vertex Pharmaceuticals Incorporated today announced management participation in TD Cowen's 46th Annual Health Care Conference ...
The Muscular Dystrophy Association (MDA) today announced Łukasz Sznajder, PhD, MSc, Assistant Professor, Department of Chemistry and Biochemistry, University of Nevada, Las Vegas (UNLV), as the first ...
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, ...
Dyne Therapeutics (NASDAQ:DYN) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing ...
Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 ---- Company on track to report ELEVATE-44-201 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results